Chloroquine
- Generic Name
- Chloroquine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3
- CAS Number
- 54-05-7
- Unique Ingredient Identifier
- 886U3H6UFF
- Background
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Chloroquine was granted FDA Approval on 31 October 1949.
- Indication
Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
Chloroquine is also used off label for the treatment of rheumatic diseases, as well as treatment and prophylaxis of Zika virus. Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.
- Associated Conditions
- Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women
- Conditions
- MalariaPregnancy
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 900
- Registration Number
- NCT00131703
Antimalarial Drug Resistance in Mali
- Conditions
- Malaria
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2006-08-16
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 1011
- Registration Number
- NCT00127998
- Locations
- 🇲🇱
Koro Health Center, Koro, Mali
🇲🇱Faladje Missionary Dispensary, Faladje, Mali
🇲🇱Pongono Community Health Center, Pongono, Mali
CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi
- Conditions
- MalariaPlasmodium Falciparum Malaria
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2010-08-27
- Target Recruit Count
- 210
- Registration Number
- NCT00125489
- Locations
- 🇲🇼
Blantyre Malaria Project, Blantyre, Malawi
Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum
- Conditions
- Malaria, Falciparum
- First Posted Date
- 2004-05-14
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00082563
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.